All In Biotech

Drug Trial Radar · NCT03117569

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis

Last checked: Nov 20, 2026Latest source record: Dec 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

380

Actual

Start

Aug 21, 2017

Primary completion

Dec 19, 2018

Study completion Dec 19, 2018

Sponsor

Lead sponsor
Kirby InstituteGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Apr 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified. Data has shown that direct acting antiviral (DAA) regimen of glecaprevir (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor respectively , provides key features for HCV treatment simplification. Eligible participants (naïve pre-cirrhosis chronic HCV patients) will be randomized (1:2) to the standard or simplified monitoring arm and will receive treatment for 8 weeks. One post treatment visit will be conducted 12 weeks after the final dose of study medication to evaluate the proportion of patients with undetectable HCV RNA at this timepoint (SVR12).

Conditions

  • Hepatitis C, Chronic

Interventions

  • glecaprevir (300mg)/pibrentasvir (120mg)Drug

    glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Undetectable HCV RNA (ITT Population)Time frame: 12 weeks post end of treatment (SVR12)

Locations

33 sites in 8 countries. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • New York University Langone Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • SSM Health Dean Medical Group

    Madison, Wisconsin

  • East Sydney Doctors

    Sydney, New South Wales, Australia

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, Australia

  • Holdsworth House Medical Practice

    Sydney, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • St Vincent's Hospital Melbourne

    Melbourne, Victoria, Australia

  • Lair Centre

    Vancouver, British Columbia, Canada

  • (G.I.R.I.) GI Research Institute

    Vancouver, British Columbia, Canada

  • William Osler Health System

    Brampton, Ontario, Canada

  • St Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • McGill University Health Centre (MUHC)

    Montreal, Quebec, Canada

  • CHU de Québec-Université Laval

    Québec, Quebec, Canada

  • Hopital Henri Mondor

    Créteil, France

  • Hopital Saint Joseph

    Marseille, France

  • Hopital Saint Antoine

    Paris, France

  • zibp - Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH

    Berlin, Germany

  • Center for HIV and Hepatogastroenterology

    Düsseldorf, Germany

  • Hannover Medical School

    Hanover, Germany

  • CIM-Centrum fuer Interdisziplinaere Medizin GmbH

    Münster, Germany

  • Auckland City Hospital

    Auckland, New Zealand

  • Calder Center

    Auckland, New Zealand

  • Christchurch Hospital

    Christchurch, New Zealand

  • Dunedin Hospital

    Dunedin, New Zealand

  • Inselspital - Universitaetsspital Bern

    Bern, Switzerland

  • University Hospital Zurich

    Zurich, Switzerland

  • Barts Health

    London, United Kingdom

  • King's College Hospital

    London, United Kingdom

  • Imperial College Healthcare NHS Trust (St Mary's Hospital)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.